Base de dados : MEDLINE
Pesquisa : C04.557.470.200.025.290 [Categoria DeCS]
Referências encontradas : 295 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 30 ir para página                         

  1 / 295 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28363070
[Au] Autor:Eustace R; Garner MM; Cook K; Miller C; Kiupel M
[Ti] Título:MULTIHORMONAL ISLET CELL CARCINOMAS IN THREE KOMODO DRAGONS (VARANUS KOMODOENSIS).
[So] Source:J Zoo Wildl Med;48(1):241-244, 2017 Mar.
[Is] ISSN:1042-7260
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Multihormonal pancreatic islet cell carcinomas were found in one female and two male captive geriatric Komodo dragons (Varanus komodoensis). Gross changes in the pancreas were visible in two of the cases. Clinical signs noted in the Komodo dragons were lethargy, weakness, and anorexia. Histologically, the tumors were comprised of nests and cords of well-differentiated neoplastic islet cells with scant amounts of eosinophilic cytoplasm and round, euchromatic nuclei, with rare mitoses. Infiltration by the islet cell tumor into the surrounding acinar tissue was observed in all cases, but no metastatic foci were seen. Multihormone expression was observed in all tumors, which labeled strongly positive for glucagon and somatostatin and focally positive for polypeptide. Pancreatic islet cell neoplasms should be considered in the differential diagnosis for geriatric Komodo dragons presenting with weakness, lethargy, and poor appetite.
[Mh] Termos MeSH primário: Carcinoma de Células das Ilhotas Pancreáticas/veterinária
Lagartos
Neoplasias Pancreáticas/veterinária
[Mh] Termos MeSH secundário: Animais
Carcinoma de Células das Ilhotas Pancreáticas/patologia
Evolução Fatal
Feminino
Masculino
Neoplasias Hormônio-Dependentes
Neoplasias Pancreáticas/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170401
[St] Status:MEDLINE
[do] DOI:10.1638/2016-0131.1


  2 / 295 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27404266
[Au] Autor:Parbhu SK; Adler DG
[Ad] Endereço:a Department of Internal Medicine, Division of Gastroenterology and Hepatology , University of Utah School of Medicine, Huntsman Cancer Center , Salt Lake City , Utah , USA.
[Ti] Título:Pancreatic neuroendocrine tumors: contemporary diagnosis and management.
[So] Source:Hosp Pract (1995);44(3):109-19, 2016 Aug.
[Is] ISSN:2154-8331
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Pancreatic neuroendocrine tumors (PNETs) are neoplasms that arise from the hormone producing cells of the islets of Langerhans, also known as pancreatic islet cells. PNETs are considered a subgroup of neuroendocrine tumors, and have unique biology, natural history and clinical management. These tumors are classified as 'functional' or 'non-functional' depending on whether they release peptide hormones that produce specific hormone- related symptoms, usually in established patterns based on tumor subtype. This manuscript will review pancreatic neuroendocrine tumor subtypes, syndromes, diagnosis, and clinical management.
[Mh] Termos MeSH primário: Tumores Neuroendócrinos/diagnóstico
Tumores Neuroendócrinos/terapia
Neoplasias Pancreáticas/diagnóstico
Neoplasias Pancreáticas/terapia
[Mh] Termos MeSH secundário: Carcinoma de Células das Ilhotas Pancreáticas/fisiopatologia
Carcinoma de Células das Ilhotas Pancreáticas/terapia
Grupos de Populações Continentais
Seres Humanos
Insulinoma/fisiopatologia
Insulinoma/terapia
Ilhotas Pancreáticas
Neoplasia Endócrina Múltipla Tipo 1/fisiopatologia
Neoplasia Endócrina Múltipla Tipo 1/terapia
Gradação de Tumores
Estadiamento de Neoplasias
Tumores Neuroendócrinos/fisiopatologia
Hormônios Pancreáticos
Neoplasias Pancreáticas/fisiopatologia
Hormônios Peptídicos
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pancreatic Hormones); 0 (Peptide Hormones)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170206
[Lr] Data última revisão:
170206
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160713
[St] Status:MEDLINE
[do] DOI:10.1080/21548331.2016.1210474


  3 / 295 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26704781
[Au] Autor:Keutgen XM; Nilubol N; Kebebew E
[Ad] Endereço:Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: xavier.keutgen@nih.gov.
[Ti] Título:Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis.
[So] Source:Surgery;159(5):1382-9, 2016 May.
[Is] ISSN:1532-7361
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Malignant-functioning pancreatic neuroendocrine tumors (mFpNETs) are rare. Research analyzing the presentation, biological behavior, and patient outcomes of these tumors is limited. METHODS: We used the Surveillance, Epidemiology, and End Results database to identify patients with malignant insulinomas, gastrinomas, glucagonomas, vasoactive intestinal peptide secreting tumors (VIPomas), somastatinomas, and mixed islet cell tumors (MICTs). The primary endpoint of this study was to identify factors affecting survival. RESULTS: We identified 401 patients with mFpNETs. Between histologic subtypes, there were significant differences in sex and age, and in tumor size, grade, location, and stage. Median survival time for insulinomas was 12.7 years; gastrinomas, 10.2 years; glucagonomas, 7.7 years; VIPomas, 7.9 years; and MICTs, 3.4 years. Multivariable analysis showed that histology (insulinoma, gastrinoma, and VIPoma; P = .009), absence of distant metastases (P = .002), age < 50 years (P = .001), surgical intervention (P = .001), and stage I/II disease (P = .011) were independently associated with prolonged survival. Subgroup analysis demonstrated that removal of the primary tumor in stage IV mFpNETs was associated with significantly prolonged survival (P = .01). CONCLUSION: mFpNETs are rare tumors that commonly present at an advanced stage despite hormonal secretion. Primary tumor resection is associated with longer survival in stages I-III as well as stage IV tumors.
[Mh] Termos MeSH primário: Carcinoma de Células das Ilhotas Pancreáticas/mortalidade
Insulinoma/mortalidade
Tumores Neuroendócrinos/mortalidade
Neoplasias Pancreáticas/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma de Células das Ilhotas Pancreáticas/patologia
Carcinoma de Células das Ilhotas Pancreáticas/cirurgia
Feminino
Seguimentos
Seres Humanos
Insulinoma/patologia
Insulinoma/cirurgia
Masculino
Meia-Idade
Análise Multivariada
Estadiamento de Neoplasias
Tumores Neuroendócrinos/patologia
Tumores Neuroendócrinos/cirurgia
Pancreatectomia
Neoplasias Pancreáticas/patologia
Neoplasias Pancreáticas/cirurgia
Estudos Retrospectivos
Programa de SEER
Análise de Sobrevida
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160406
[Lr] Data última revisão:
160406
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:151226
[St] Status:MEDLINE


  4 / 295 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25832942
[Au] Autor:Yoshioka M; Shibata S; Uchinami H; Watanabe G; Miyazawa H; Iida M; Yoshida M; Yoshioka T; Nanjo H; Yamamoto Y
[Ad] Endereço:Department of Gastroenterological Surgery, Akita University Graduate School of Medicine, Japan.
[Ti] Título:The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
[So] Source:Intern Med;54(7):785-90, 2015.
[Is] ISSN:1349-7235
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:We herein report the first case of a nonfunctioning islet cell tumor that transformed into a proinsulinoma during the process of metastasis to the lungs. This phenomenon was confirmed in a 69-year-old woman with an advanced pancreatic islet cell tumor and multiple liver metastases who later developed multiple lung metastases. She underwent pancreatic resection followed by the administration of chemotherapy and survived for seven years. Although the patient initially had hyperglycemia due to diabetes mellitus, she conversely began to manifest hypoglycemic attacks 63 months postoperatively with the concomitant development of multiple lung metastases. An autopsy revealed that only the tumor in the lungs produced proinsulin; no other hormones were detected.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma de Células das Ilhotas Pancreáticas/patologia
Hipoglicemia/prevenção & controle
Neoplasias Pulmonares/secundário
Neoplasias Pancreáticas/patologia
[Mh] Termos MeSH secundário: Idoso
Carcinoma de Células das Ilhotas Pancreáticas/metabolismo
Carcinoma de Células das Ilhotas Pancreáticas/terapia
Colectomia
Desoxicitidina/administração & dosagem
Desoxicitidina/análogos & derivados
Diazóxido/administração & dosagem
Progressão da Doença
Evolução Fatal
Feminino
Fluoruracila/administração & dosagem
Gastrectomia
Seres Humanos
Hipoglicemia/complicações
Neoplasias Pulmonares/terapia
Mitomicina/administração & dosagem
Nefrectomia
Octreotida/administração & dosagem
Pancreatectomia
Neoplasias Pancreáticas/metabolismo
Neoplasias Pancreáticas/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0W860991D6 (Deoxycytidine); 50SG953SK6 (Mitomycin); B76N6SBZ8R (gemcitabine); O5CB12L4FN (Diazoxide); RWM8CCW8GP (Octreotide); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:150402
[Lr] Data última revisão:
150402
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150403
[St] Status:MEDLINE
[do] DOI:10.2169/internalmedicine.54.3772


  5 / 295 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24446791
[Au] Autor:Pieczarka EM; Russell DS; Santangelo KS; Aeffner F; Burkhard MJ
[Ad] Endereço:Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
[Ti] Título:Osseous metaplasia within a canine insulinoma.
[So] Source:Vet Clin Pathol;43(1):89-93, 2014 Mar.
[Is] ISSN:1939-165X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:An 11-year-old male castrated mixed-breed dog was presented for exercise intolerance, tetraparesis, and persistent hypoglycemia. Abdominal ultrasound examination revealed 2 nodules within the right limb of the pancreas. Cytology from one nodule was consistent with a carcinoma of neuroendocrine origin, with a primary differential diagnosis of insulinoma. Histologic evaluation and immunohistochemistry for synaptophysin and insulin confirmed the diagnosis of insulinoma. Additionally, there was a solitary nodule of mineralized compact bone composing approximately 60% of the mass. To the authors' knowledge, this is the first report of osseous metaplasia within an insulinoma (islet cell carcinoma).
[Mh] Termos MeSH primário: Carcinoma de Células das Ilhotas Pancreáticas/veterinária
Doenças do Cão/patologia
Hipoglicemia/veterinária
Insulinoma/veterinária
Neoplasias Pancreáticas/veterinária
[Mh] Termos MeSH secundário: Animais
Biópsia por Agulha Fina/veterinária
Osso e Ossos/patologia
Carcinoma de Células das Ilhotas Pancreáticas/patologia
Diagnóstico Diferencial
Cães
Eutanásia Animal
Hipoglicemia/patologia
Insulina/metabolismo
Insulinoma/patologia
Masculino
Metaplasia
Ohio
Pâncreas/patologia
Neoplasias Pancreáticas/patologia
Sinaptofisina/metabolismo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); 0 (Synaptophysin)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140123
[St] Status:MEDLINE
[do] DOI:10.1111/vcp.12117


  6 / 295 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24394744
[Au] Autor:Berends M; Lesterhuis WJ; van Laarhoven HW
[Ad] Endereço:Department of Internal Medicine, Maasziekenhuis Pantein, Boxmeer, the Netherlands.
[Ti] Título:Streptozotocin-induced diabetic ketoacidosis in a patient with metastatic islet-cell carcinoma.
[So] Source:Neth J Med;71(10):541-2, 2013 Dec.
[Is] ISSN:1872-9061
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Here we report a severe life-threatening complication of treatment with streptozotocin in a patient with pancreatic island-cell carcinoma. The patient was admitted to the intensive care unit with severe diabetic ketoacidosis which needed aggressive fluid resuscitation and insulin therapy. We believe it is critical to be aware of the symptoms of diabetic ketoacidosis and monitor glucose levels during streptozotocin treatment.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/efeitos adversos
Cetoacidose Diabética/induzido quimicamente
Cetoacidose Diabética/diagnóstico
Estreptozocina/efeitos adversos
[Mh] Termos MeSH secundário: Antibióticos Antineoplásicos/uso terapêutico
Carcinoma de Células das Ilhotas Pancreáticas/tratamento farmacológico
Diagnóstico Diferencial
Feminino
Seres Humanos
Meia-Idade
Debilidade Muscular/etiologia
Neoplasias Pancreáticas/tratamento farmacológico
Estreptozocina/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 5W494URQ81 (Streptozocin)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:140107
[Lr] Data última revisão:
140107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140108
[St] Status:MEDLINE


  7 / 295 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23771245
[Au] Autor:Kuo EJ; Salem RR
[Ad] Endereço:Section of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA.
[Ti] Título:Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
[So] Source:Ann Surg Oncol;20(9):2815-21, 2013 Sep.
[Is] ISSN:1534-4681
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: There is a paucity of evidence regarding incidence and predictors of survival in pancreatic neuroendocrine tumors (PNETs)≤2 cm in size. METHODS: Patients having undergone resection for nonfunctioning PNETs were selected from the SEER database (1988-2009) and an institutional pathology database (1996-2012). PNETs≤2 cm were compared with PNETs>2 cm. Data were analyzed with χ2 tests, ANOVA, the Kaplan-Meier method, log rank tests, and Cox proportional hazard, and binary logistic regression. RESULTS: The incidence of PNETs≤2 cm in the United States has increased by 710.4% over the last 22 years. Rates of extrapancreatic extension, nodal metastasis, and distant metastasis in PNETs≤2 cm in the SEER database were 17.9, 27.3, and 9.1%, respectively. The rate of nodal metastasis in our institutional series was 5.7%. Disease-specific survival at 5, 10, and 15 years for PNETs≤2 cm was 91.5, 84.0, and 76.8%. Decreased disease-specific survival was not associated with nodal metastasis, but rather with high grade [moderately differentiated, hazard ratio (HR) 37.2, 95% confidence interval (CI) 2.7-518.8; poorly differentiated, HR 94.2, 95% CI 4.9-1,794.4; reference, well differentiated], and minority race (Asian, HR 30.2, 95% CI 3.1-291.7; Black, HR 60.1, 95% CI 2.1-1,027.9; reference, White). CONCLUSIONS: Pancreatic neuroendocrine tumors≤2 cm are increasingly common, and the most significant predictors of disease-specific survival are grade and race. The SEER database excludes PNETs considered to be benign, and rates of extrapancreatic extension, nodal metastasis, and distant metastasis are overestimated. Small size, however, does not preclude malignant behavior.
[Mh] Termos MeSH primário: Adenocarcinoma/epidemiologia
Tumor Carcinoide/epidemiologia
Carcinoma de Células das Ilhotas Pancreáticas/epidemiologia
Tumores Neuroendócrinos/epidemiologia
Neoplasias Pancreáticas/epidemiologia
[Mh] Termos MeSH secundário: Adenocarcinoma/mortalidade
Adenocarcinoma/patologia
Adolescente
Adulto
Idoso
Tumor Carcinoide/mortalidade
Tumor Carcinoide/patologia
Carcinoma de Células das Ilhotas Pancreáticas/mortalidade
Carcinoma de Células das Ilhotas Pancreáticas/patologia
Connecticut/epidemiologia
Feminino
Seguimentos
Seres Humanos
Incidência
Metástase Linfática
Masculino
Meia-Idade
Estadiamento de Neoplasias
Tumores Neuroendócrinos/mortalidade
Tumores Neuroendócrinos/patologia
Neoplasias Pancreáticas/mortalidade
Neoplasias Pancreáticas/patologia
Prognóstico
Fatores de Risco
Programa de SEER
Taxa de Sobrevida
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1403
[Cu] Atualização por classe:130805
[Lr] Data última revisão:
130805
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130618
[St] Status:MEDLINE
[do] DOI:10.1245/s10434-013-3005-7


  8 / 295 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23657967
[Au] Autor:Annaratone L; Volante M; Asioli S; Rangel N; Bussolati G
[Ad] Endereço:Department of Medical Sciences, University of Turin, Via Santena 7, 10126, Turin, Italy.
[Ti] Título:Characterization of neuroendocrine tumors of the pancreas by real-time quantitative polymerase chain reaction. A methodological approach.
[So] Source:Endocr Pathol;24(2):83-91, 2013 Jun.
[Is] ISSN:1559-0097
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to assess the suitability of using real-time quantitative PCR (RT-qPCR) to characterize neuroendocrine (NE) tumors of the pancreas. For a series of tumors, we evaluated several genes of interest, and the data were matched with the "classical" immunohistochemical (IHC) features. In 21 cases, we extracted RNA from formalin-fixed paraffin-embedded (FFPE) blocks, and in nine cases, we also extracted RNA from fresh-frozen tissue. The RT-qPCR procedure was performed using two sets of customized arrays. The test using the first set, covering 96 genes of interest, was focused on assessing the feasibility of the procedure, and the results were used to select 18 genes indicative of NE differentiation, clinical behavior, and therapeutic responsiveness for use in the second set of arrays. Threshold cycle (Ct) values were used to calculate the fold-changes in gene expression using the 2-∆∆Ct method. Statistical procedures were used to analyze the results, which were matched with the IHC and follow-up data. Material from fresh-frozen samples performed better in terms of the level of amplification, but acceptable and concordant results were also obtained from FFPE samples. In addition, high concordance was observed between the mRNA and protein expression levels of somatostatin receptor type 2A (R = 0.52, p = 0.016). Genes associated with NE differentiation, as well as the gastrin-releasing peptide receptor and O-6-methylguanine-DNA methyltransferase genes, were underexpressed, whereas angiogenesis-associated markers (CDH13 and SLIT2) were overexpressed in tissues with malignant behavior. The RT-qPCR procedure is practical and feasible in economic terms for the characterization of NE tumors of the pancreas and can complement morphological and IHC-based evaluations. Thus, the results of the RT-qPCR procedure might offer an objective basis for therapeutic choices.
[Mh] Termos MeSH primário: Carcinoma de Células das Ilhotas Pancreáticas/patologia
Regulação Neoplásica da Expressão Gênica
Neoplasias Pancreáticas/patologia
Reação em Cadeia da Polimerase em Tempo Real/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/genética
Biomarcadores Tumorais/metabolismo
Carcinoma de Células das Ilhotas Pancreáticas/genética
Carcinoma de Células das Ilhotas Pancreáticas/metabolismo
DNA de Neoplasias/análise
Feminino
Secções Congeladas
Seres Humanos
Imuno-Histoquímica/métodos
Masculino
Meia-Idade
Neoplasias Pancreáticas/genética
Neoplasias Pancreáticas/metabolismo
RNA Mensageiro/metabolismo
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (DNA, Neoplasm); 0 (RNA, Messenger)
[Em] Mês de entrada:1312
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130510
[St] Status:MEDLINE
[do] DOI:10.1007/s12022-013-9246-y


  9 / 295 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23462323
[Au] Autor:Yu R; Jih L; Zhai J; Nissen NN; Colquhoun S; Wolin E; Dhall D
[Ad] Endereço:Division of Endocrinology, Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. run.yu@cshs.org
[Ti] Título:Mixed acinar-endocrine carcinoma of the pancreas: new clinical and pathological features in a contemporary series.
[So] Source:Pancreas;42(3):429-35, 2013 Apr.
[Is] ISSN:1536-4828
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The objective of this study was to characterize the novel clinical and pathological features of mixed acinar-endocrine carcinoma of the pancreas. METHODS: This was a retrospective review of medical records and surgical pathology specimens of patients with a diagnosis of mixed acinar-endocrine carcinoma of the pancreas at Cedars-Sinai Medical Center between 2005 and 2011. Additional immunohistochemistry was performed on the specimens of some patients. RESULTS: Five patients were identified. The median age at presentation was 74 years (range, 59-89 years), and all patients were male. The presenting symptoms were all related to tumor mass effects. The median size of the tumor was 10 cm (range, 3.9-16 cm). Preoperative clinical diagnosis aided by fine-needle aspiration biopsy was incorrect in all 5 cases. Most tumors (3/5) exhibited predominantly endocrine differentiation without hormonal production. Only 10% to 30% of cells were truly amphicrine, whereas most were differentiated into either endocrine or acinar phenotype. The clinical behavior ranged from moderate to aggressive with postoperative survival from 2.5 months to more than 3 years. Four patients received neoadjuvant or adjuvant chemotherapy with variable responses. CONCLUSIONS: Mixed acinar-endocrine carcinoma of the pancreas appears to be not uncommon in men, may harbor predominantly endocrine component, is often misdiagnosed by cytology, and exhibits variable clinical behavior. Mixed acinar-endocrine carcinoma of the pancreas should be considered in older patients with sizable pancreatic mass and may warrant aggressive surgical resection and chemotherapy.
[Mh] Termos MeSH primário: Carcinoma de Células Acinares/patologia
Carcinoma de Células das Ilhotas Pancreáticas/patologia
Pâncreas/patologia
Neoplasias Pancreáticas/patologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Biópsia por Agulha Fina
Carcinoma de Células Acinares/tratamento farmacológico
Carcinoma de Células Acinares/cirurgia
Carcinoma de Células das Ilhotas Pancreáticas/tratamento farmacológico
Carcinoma de Células das Ilhotas Pancreáticas/cirurgia
Diagnóstico Diferencial
Seres Humanos
Masculino
Meia-Idade
Pâncreas/efeitos dos fármacos
Pâncreas/cirurgia
Neoplasias Pancreáticas/tratamento farmacológico
Neoplasias Pancreáticas/cirurgia
Estudos Retrospectivos
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1308
[Cu] Atualização por classe:130315
[Lr] Data última revisão:
130315
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130307
[St] Status:MEDLINE
[do] DOI:10.1097/MPA.0b013e318264d073


  10 / 295 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22135173
[Au] Autor:Kleine M; Schrem H; Vondran FW; Krech T; Klempnauer J; Bektas H
[Ad] Endereço:Department of General, Visceral and Transplant Surgery, Hanover, Germany. kleine.moritz@mh-hannover.de
[Ti] Título:Extended surgery for advanced pancreatic endocrine tumours.
[So] Source:Br J Surg;99(1):88-94, 2012 Jan.
[Is] ISSN:1365-2168
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pancreatic endocrine tumours are often diagnosed at an advanced stage with hepatic metastasis. This study investigated whether extended resections for advanced malignant pancreatic endocrine tumours influenced disease-free and disease-specific survival. METHODS: Patients who had curative resection of pancreatic endocrine tumours were analysed retrospectively for disease-free and disease-specific survival, with a focus on the role of extended surgical resection. RESULTS: Forty-one patients were included in the analysis, 13 of whom underwent extended surgical resection in addition to pancreatic resection. This included partial liver resection in nine patients, portal vein resection in three, partial gastric resection in five and liver transplantation in three patients. There were no deaths in hospital or within 30 days. Median follow-up was 40 (range 2-239) months. Thirty-five, 24 and 13 patients survived more than 1, 3 and 5 years respectively. Patients who underwent extended resection had similar disease-specific survival to those who had pancreatic resection alone (hazard ratio (HR) 1·50, 95 per cent confidence interval (c.i.) 0·35 to 6·35; P = 0·581) but with a higher frequency of complications (odds ratio (OR) 4·28, 95 per cent c.i. 1·04 to 17·62; P = 0·044). Among patients with liver metastases, the mortality rate was higher in those in whom liver resection was not possible than in patients who had liver resection (HR 9·24, 1·00 to 85·18; P = 0·049). Patients who had liver resection had similar disease-specific survival to those without liver metastases (HR 0·84, 0·09 to 7·57; P = 0·877). CONCLUSION: Extended surgical resection for locally advanced and metastatic pancreatic endocrine tumours is feasible with encouraging disease-specific survival.
[Mh] Termos MeSH primário: Neoplasias Hepáticas/mortalidade
Neoplasias Hepáticas/secundário
Tumores Neuroendócrinos/mortalidade
Tumores Neuroendócrinos/cirurgia
Neoplasias Pancreáticas/mortalidade
Neoplasias Pancreáticas/cirurgia
[Mh] Termos MeSH secundário: Adulto
Idoso
Carcinoma de Células das Ilhotas Pancreáticas/mortalidade
Carcinoma de Células das Ilhotas Pancreáticas/cirurgia
Intervalo Livre de Doença
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Tumores Neuroendócrinos/patologia
Razão de Chances
Neoplasias Pancreáticas/patologia
Estudos Retrospectivos
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1201
[Cu] Atualização por classe:111202
[Lr] Data última revisão:
111202
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:111203
[St] Status:MEDLINE
[do] DOI:10.1002/bjs.7681



página 1 de 30 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde